DFTX

+ Watchlist + Portfolio

Definium Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $45.82
52-Week Range: $8.70 – $49.70
Market Cap: $6.10B
P/E (TTM): —
EPS (TTM): -3.43
Dividend Yield: —

Advanced Metrics

Price/Book: 6.64
PEG Ratio: —
Return on Equity: -64.09%
Return on Assets: -20.64%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 6.95
Debt/Equity: 0.04
Total Debt: $36.47M
Free Cash Flow: $7.61M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $5.11B

DFTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$36.17M	$52.12M	$65.30M	$117.67M
Selling, General & Admin	$30.16M	$41.74M	$38.62M	$48.64M
Operating Expenses	$66.33M	$93.87M	$103.92M	$166.31M
Operating Income	-$66.33M	-$93.87M	-$103.92M	-$166.31M
EBITDA	-$63.15M	-$91.65M	-$105.87M	-$178.31M
Pretax Income	-$56.80M	-$95.73M	-$108.68M	-$183.79M
Income Tax	$0.00	—	—	—
Net Income	-$56.80M	-$95.73M	-$108.68M	-$183.79M
Diluted EPS	-1.84	-2.44	-1.54	-2.06
Diluted Shares	30.86M	39.16M	70.46M	89.33M

DFTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$142.14M	$99.70M	$273.74M	$257.84M
Current Assets	$146.06M	$103.87M	$281.62M	$419.32M
Total Assets	$169.99M	$124.54M	$302.15M	$440.10M
Current Liabilities	$17.89M	$32.25M	$38.85M	$66.70M
Long-Term Debt	—	$14.13M	$21.85M	$40.58M
Total Debt	$72.00K	$14.13M	$21.85M	$40.58M
Total Liabilities	$19.08M	$46.41M	$60.70M	$107.77M
Retained Earnings	-$194.47M	-$290.20M	-$398.88M	-$582.67M
Shareholders' Equity	$150.92M	$78.13M	$241.45M	$332.33M
Working Capital	$128.16M	$71.63M	$242.77M	$352.62M

DFTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$50.14M	-$64.36M	-$79.13M	-$131.56M
Free Cash Flow	-$50.14M	-$64.36M	-$79.13M	-$131.56M
Depreciation & Amortisation	$3.18M	$3.16M	$527.00K	$0.00
Stock-Based Compensation	$13.71M	$15.18M	$16.91M	$20.10M
Investing Cash Flow	$0.00	—	$0.00	-$151.61M
Financing Cash Flow	$59.05M	$21.85M	$253.20M	$267.27M
Net Change in Cash	$8.91M	-$42.52M	$174.07M	-$15.90M

DFTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$23.36M	$29.81M	$30.98M	$33.52M	$41.48M
Selling, General & Admin	$8.80M	$11.09M	$14.69M	$14.06M	$17.74M
Operating Expenses	$32.16M	$40.90M	$45.67M	$47.58M	$59.22M
Operating Income	-$32.16M	-$40.90M	-$45.67M	-$47.58M	-$59.22M
EBITDA	-$22.75M	-$40.41M	-$65.99M	-$49.17M	-$75.85M
Pretax Income	-$23.35M	-$42.74M	-$67.27M	-$50.44M	-$77.10M
Net Income	-$23.35M	-$42.74M	-$67.27M	-$50.44M	-$77.10M
Diluted EPS	-0.35	-0.50	-0.78	—	-0.71
Diluted Shares	87.09M	85.35M	85.89M	—	108.79M

DFTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$82.85M	$33.39M	$19.96M	$257.84M	$262.52M
Current Assets	$221.70M	$189.14M	$215.85M	$419.32M	$380.56M
Total Assets	$275.32M	$265.09M	$236.92M	$440.10M	$401.29M
Current Liabilities	$30.48M	$37.96M	$65.42M	$66.70M	$81.11M
Long-Term Debt	$22.04M	$41.19M	$40.38M	$40.58M	$40.77M
Total Debt	$22.04M	$41.19M	$40.38M	$40.58M	$40.77M
Total Liabilities	$52.52M	$79.69M	$106.32M	$107.77M	$122.44M
Retained Earnings	-$422.23M	-$464.97M	-$532.24M	-$582.67M	-$659.77M
Shareholders' Equity	$222.81M	$185.40M	$130.60M	$332.33M	$278.85M
Working Capital	$191.22M	$151.18M	$150.43M	$352.62M	$299.45M
Net Debt	—	$7.80M	$20.43M	—	—

DFTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$29.42M	-$29.60M	-$29.57M	-$42.98M	-$42.63M
Free Cash Flow	-$29.42M	-$29.60M	-$29.57M	-$42.98M	-$42.63M
Depreciation & Amortisation	$0.00	$0.00	$0.00	$0.00	—
Stock-Based Compensation	$3.43M	$5.25M	$5.82M	$5.60M	$7.13M
Investing Cash Flow	-$162.46M	-$39.54M	$15.41M	$34.98M	$42.00M
Financing Cash Flow	$1.00M	$19.65M	$749.00K	$245.87M	$5.31M
Net Change in Cash	-$190.88M	-$49.49M	-$13.41M	$237.88M	$4.68M

Market Snapshot

About

Definium Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for rare genetic diseases caused by protein misfolding. The company's lead programs target cystic fibrosis and alpha-1 antitrypsin deficiency using small molecule chaperone therapeutics designed to correct the folding and trafficking of mutant proteins. Definium's platform technology aims to restore protein function by stabilizing cellular proteins in their proper three-dimensional structure. The company advances drug candidates through preclinical and clinical development with the goal of addressing significant unmet medical needs in genetic disorders.